Psoriasiform reactions during treatment with abatacept
Triggering or worsening of psoriasis has been traditionally reported in patients treated with each of the three currently available tumor necrosis factor (TNF)-α blocking agents (infliximab, etanercept and adalimumab). [2],[4],[5] In a meta-analysis of 13 relevant trials, four of 1332 RA patients w...
Gespeichert in:
| Veröffentlicht in: | Indian journal of dermatology, venereology, and leprology venereology, and leprology, 2014-01, Vol.80 (1), p.92 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 92 |
| container_title | Indian journal of dermatology, venereology, and leprology |
| container_volume | 80 |
| creator | Conde-Montero, Elena Baniandrés-Rodríguez, Ofelia Mendoza-Cembranos, María Dolores Horcajada-Reales, Celia Suárez-Fernández, Ricardo |
| description | Triggering or worsening of psoriasis has been traditionally reported in patients treated with each of the three currently available tumor necrosis factor (TNF)-α blocking agents (infliximab, etanercept and adalimumab). [2],[4],[5] In a meta-analysis of 13 relevant trials, four of 1332 RA patients who received abatacept as monotherapy as well as 13 of 1945 patients treated with abatacept plus disease-modifying antirheumatic drugs developed psoriasis as an adverse event. |
| doi_str_mv | 10.4103/0378-6323.125502 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_1497207694</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A358217133</galeid><sourcerecordid>A358217133</sourcerecordid><originalsourceid>FETCH-LOGICAL-c472t-dbc413e41fbb3ede70f30d334eb747d8d610bc3a82d42412e455c0176ed9773</originalsourceid><addsrcrecordid>eNptkUFr3DAQRkVoadIk956KodCbt5JmbNnHENqkEGghuQtZGu8q2NZGkgn59_V2k6aBRQeJ0ftmYB5jnwRfoeDwjYNqyhokrISsKi6P2AlvFZTQSvlueb98H7OPKd1zLrEG8YEdS0RsBOIJq3-nEL1Jvg9xLCIZm32YUuHm6Kd1kZdKHmnKxaPPm8J0JhtL23zG3vdmSHT-fJ-y2x_f7y6vy5tfVz8vL25Ki0rm0nUWBRCKvuuAHCneA3cASJ1C5RpXC95ZMI10KFFIwqqyXKiaXKsUnLIv-67bGB5mSlnfhzlOy0AtsFWSq7rFV2ptBtJ-6kOOxo4-WX0BVSOFEgALVR6g1jRRNEOYqPdL-Q2_OsAvx9Ho7cHA1_8CGzJD3qQwzH_3-Rbke9DGkFKkXm-jH0180oLrnVa986Z33vRe6xL5_LyIuRvJ_Qu8eIQ_EG6ZKw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1497207694</pqid></control><display><type>article</type><title>Psoriasiform reactions during treatment with abatacept</title><source>MEDLINE</source><source>Bioline International</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Conde-Montero, Elena ; Baniandrés-Rodríguez, Ofelia ; Mendoza-Cembranos, María Dolores ; Horcajada-Reales, Celia ; Suárez-Fernández, Ricardo</creator><creatorcontrib>Conde-Montero, Elena ; Baniandrés-Rodríguez, Ofelia ; Mendoza-Cembranos, María Dolores ; Horcajada-Reales, Celia ; Suárez-Fernández, Ricardo</creatorcontrib><description>Triggering or worsening of psoriasis has been traditionally reported in patients treated with each of the three currently available tumor necrosis factor (TNF)-α blocking agents (infliximab, etanercept and adalimumab). [2],[4],[5] In a meta-analysis of 13 relevant trials, four of 1332 RA patients who received abatacept as monotherapy as well as 13 of 1945 patients treated with abatacept plus disease-modifying antirheumatic drugs developed psoriasis as an adverse event.</description><identifier>ISSN: 0378-6323</identifier><identifier>EISSN: 0973-3922</identifier><identifier>EISSN: 1998-3611</identifier><identifier>DOI: 10.4103/0378-6323.125502</identifier><identifier>PMID: 24448144</identifier><language>eng</language><publisher>India: Medknow Publications and Media Pvt. Ltd</publisher><subject>Abatacept ; Abatacept - adverse effects ; Adult ; Antirheumatic Agents - adverse effects ; Arthritis ; Case studies ; Diagnosis ; Disease Progression ; Drug Eruptions - etiology ; Drug Eruptions - pathology ; Drug therapy ; Female ; Health aspects ; Humans ; Male ; Middle Aged ; Patient outcomes ; Psoriasis ; Psoriasis - chemically induced ; Psoriasis - pathology ; Risk factors</subject><ispartof>Indian journal of dermatology, venereology, and leprology, 2014-01, Vol.80 (1), p.92</ispartof><rights>COPYRIGHT 2014 Medknow Publications and Media Pvt. Ltd.</rights><rights>Copyright Medknow Publications & Media Pvt Ltd Jan-Feb 2014</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c472t-dbc413e41fbb3ede70f30d334eb747d8d610bc3a82d42412e455c0176ed9773</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4022,27922,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24448144$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Conde-Montero, Elena</creatorcontrib><creatorcontrib>Baniandrés-Rodríguez, Ofelia</creatorcontrib><creatorcontrib>Mendoza-Cembranos, María Dolores</creatorcontrib><creatorcontrib>Horcajada-Reales, Celia</creatorcontrib><creatorcontrib>Suárez-Fernández, Ricardo</creatorcontrib><title>Psoriasiform reactions during treatment with abatacept</title><title>Indian journal of dermatology, venereology, and leprology</title><addtitle>Indian J Dermatol Venereol Leprol</addtitle><description>Triggering or worsening of psoriasis has been traditionally reported in patients treated with each of the three currently available tumor necrosis factor (TNF)-α blocking agents (infliximab, etanercept and adalimumab). [2],[4],[5] In a meta-analysis of 13 relevant trials, four of 1332 RA patients who received abatacept as monotherapy as well as 13 of 1945 patients treated with abatacept plus disease-modifying antirheumatic drugs developed psoriasis as an adverse event.</description><subject>Abatacept</subject><subject>Abatacept - adverse effects</subject><subject>Adult</subject><subject>Antirheumatic Agents - adverse effects</subject><subject>Arthritis</subject><subject>Case studies</subject><subject>Diagnosis</subject><subject>Disease Progression</subject><subject>Drug Eruptions - etiology</subject><subject>Drug Eruptions - pathology</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Patient outcomes</subject><subject>Psoriasis</subject><subject>Psoriasis - chemically induced</subject><subject>Psoriasis - pathology</subject><subject>Risk factors</subject><issn>0378-6323</issn><issn>0973-3922</issn><issn>1998-3611</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkUFr3DAQRkVoadIk956KodCbt5JmbNnHENqkEGghuQtZGu8q2NZGkgn59_V2k6aBRQeJ0ftmYB5jnwRfoeDwjYNqyhokrISsKi6P2AlvFZTQSvlueb98H7OPKd1zLrEG8YEdS0RsBOIJq3-nEL1Jvg9xLCIZm32YUuHm6Kd1kZdKHmnKxaPPm8J0JhtL23zG3vdmSHT-fJ-y2x_f7y6vy5tfVz8vL25Ki0rm0nUWBRCKvuuAHCneA3cASJ1C5RpXC95ZMI10KFFIwqqyXKiaXKsUnLIv-67bGB5mSlnfhzlOy0AtsFWSq7rFV2ptBtJ-6kOOxo4-WX0BVSOFEgALVR6g1jRRNEOYqPdL-Q2_OsAvx9Ho7cHA1_8CGzJD3qQwzH_3-Rbke9DGkFKkXm-jH0180oLrnVa986Z33vRe6xL5_LyIuRvJ_Qu8eIQ_EG6ZKw</recordid><startdate>201401</startdate><enddate>201401</enddate><creator>Conde-Montero, Elena</creator><creator>Baniandrés-Rodríguez, Ofelia</creator><creator>Mendoza-Cembranos, María Dolores</creator><creator>Horcajada-Reales, Celia</creator><creator>Suárez-Fernández, Ricardo</creator><general>Medknow Publications and Media Pvt. Ltd</general><general>Scientific Scholar</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope></search><sort><creationdate>201401</creationdate><title>Psoriasiform reactions during treatment with abatacept</title><author>Conde-Montero, Elena ; Baniandrés-Rodríguez, Ofelia ; Mendoza-Cembranos, María Dolores ; Horcajada-Reales, Celia ; Suárez-Fernández, Ricardo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c472t-dbc413e41fbb3ede70f30d334eb747d8d610bc3a82d42412e455c0176ed9773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Abatacept</topic><topic>Abatacept - adverse effects</topic><topic>Adult</topic><topic>Antirheumatic Agents - adverse effects</topic><topic>Arthritis</topic><topic>Case studies</topic><topic>Diagnosis</topic><topic>Disease Progression</topic><topic>Drug Eruptions - etiology</topic><topic>Drug Eruptions - pathology</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Patient outcomes</topic><topic>Psoriasis</topic><topic>Psoriasis - chemically induced</topic><topic>Psoriasis - pathology</topic><topic>Risk factors</topic><toplevel>online_resources</toplevel><creatorcontrib>Conde-Montero, Elena</creatorcontrib><creatorcontrib>Baniandrés-Rodríguez, Ofelia</creatorcontrib><creatorcontrib>Mendoza-Cembranos, María Dolores</creatorcontrib><creatorcontrib>Horcajada-Reales, Celia</creatorcontrib><creatorcontrib>Suárez-Fernández, Ricardo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><jtitle>Indian journal of dermatology, venereology, and leprology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Conde-Montero, Elena</au><au>Baniandrés-Rodríguez, Ofelia</au><au>Mendoza-Cembranos, María Dolores</au><au>Horcajada-Reales, Celia</au><au>Suárez-Fernández, Ricardo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Psoriasiform reactions during treatment with abatacept</atitle><jtitle>Indian journal of dermatology, venereology, and leprology</jtitle><addtitle>Indian J Dermatol Venereol Leprol</addtitle><date>2014-01</date><risdate>2014</risdate><volume>80</volume><issue>1</issue><spage>92</spage><pages>92-</pages><issn>0378-6323</issn><eissn>0973-3922</eissn><eissn>1998-3611</eissn><abstract>Triggering or worsening of psoriasis has been traditionally reported in patients treated with each of the three currently available tumor necrosis factor (TNF)-α blocking agents (infliximab, etanercept and adalimumab). [2],[4],[5] In a meta-analysis of 13 relevant trials, four of 1332 RA patients who received abatacept as monotherapy as well as 13 of 1945 patients treated with abatacept plus disease-modifying antirheumatic drugs developed psoriasis as an adverse event.</abstract><cop>India</cop><pub>Medknow Publications and Media Pvt. Ltd</pub><pmid>24448144</pmid><doi>10.4103/0378-6323.125502</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0378-6323 |
| ispartof | Indian journal of dermatology, venereology, and leprology, 2014-01, Vol.80 (1), p.92 |
| issn | 0378-6323 0973-3922 1998-3611 |
| language | eng |
| recordid | cdi_proquest_journals_1497207694 |
| source | MEDLINE; Bioline International; EZB-FREE-00999 freely available EZB journals |
| subjects | Abatacept Abatacept - adverse effects Adult Antirheumatic Agents - adverse effects Arthritis Case studies Diagnosis Disease Progression Drug Eruptions - etiology Drug Eruptions - pathology Drug therapy Female Health aspects Humans Male Middle Aged Patient outcomes Psoriasis Psoriasis - chemically induced Psoriasis - pathology Risk factors |
| title | Psoriasiform reactions during treatment with abatacept |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T04%3A24%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Psoriasiform%20reactions%20during%20treatment%20with%20abatacept&rft.jtitle=Indian%20journal%20of%20dermatology,%20venereology,%20and%20leprology&rft.au=Conde-Montero,%20Elena&rft.date=2014-01&rft.volume=80&rft.issue=1&rft.spage=92&rft.pages=92-&rft.issn=0378-6323&rft.eissn=0973-3922&rft_id=info:doi/10.4103/0378-6323.125502&rft_dat=%3Cgale_proqu%3EA358217133%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1497207694&rft_id=info:pmid/24448144&rft_galeid=A358217133&rfr_iscdi=true |